Quest Laboratories First Half 2025 Earnings: EPS: ₹4.89 (vs ₹4.42 in 1H 2024)
Quest Laboratories (NSE:QUESTLAB) First Half 2025 Results
Key Financial Results
- Revenue: ₹434.6m (up 6.0% from 1H 2024).
- Net income: ₹80.1m (up 46% from 1H 2024).
- Profit margin: 18% (up from 13% in 1H 2024).
- EPS: ₹4.89 (up from ₹4.42 in 1H 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Quest Laboratories shares are up 7.4% from a week ago.
Risk Analysis
Be aware that Quest Laboratories is showing 2 warning signs in our investment analysis and 1 of those doesn't sit too well with us...
Valuation is complex, but we're here to simplify it.
Discover if Quest Laboratories might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NSEI:QUESTLAB
Quest Laboratories
Engages in the manufacture and sale of pharmaceutical formulations in India.
Proven track record with adequate balance sheet.